Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.8252W HIGH $23.29
Volume
1.57 M
Value Traded
18.52 M
Short % Float
11.93%
-0.47%Week
+20.7%1 Month
+9.55%3 Month
-5.16%6 Month
-45.91%5 Year
-92.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.65 B
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
2.17 B
Total Shares
154.45 M
Float Shares
120.98 M
Insiders
21.67%
Institutions
74.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATEC Catalyst Timeline
Dated clinical, regulatory and corporate events for Alphatec Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alphatec Holdings, Inc.
6Total events
1Upcoming
0Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 1
TBD
T2R&D Day
Subscribe to view catalyst details
Event history 5
●R&D DayPresentation
Management to host one-on-one investor meetings at 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
●Grant / FundingCorporate
Compensation Committee approved inducement RSU grants to 22 new employees
●Timing GuidancePresentation
Company expects FY2024 non-GAAP adjusted EBITDA of approximately $22 million
Past FDA Catalysts and PDUFA Decisions
How ATEC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Alphatec Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ATEC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Miles PatrickDirector, Officer (CEO) | Buy | 115,000 5,893,551 held | $8.81 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATEC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.4 % (-55.6 %) | 3.89 M | 449.94 K | -45.38% ( -373.82 K) |
ATEC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATEC ranks across every disease it competes in
Competitive Position is a premium feature
See how ATEC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATEC News
ATECATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
Alphatec Holdings, Inc. has appointed Tommy Carls as Executive Vice President of Data Intelligence and Strategy. This newly created position aims to strengthen the company's leadership in spine surgery solutions. Carls will report directly to CEO Pat Miles and is expected to contribute significantly to ATEC's strategic initiatives.
Read more →ATEC▼ -7.5%on this news
ATEC Reports Second Quarter Financial Results
Alphatec Holdings, Inc. reported its financial results for Q2 2026, showcasing total revenue of $214 million. The company achieved a GAAP gross margin of 72.2% and a non-GAAP gross margin of 72.5%. However, operating expenses were notably high at $156 million, which could affect profitability moving forward.
Read more →ATEC▲ +7.5%on this news
ATEC Announces Participation in Upcoming Investor Conferences
Alphatec Holdings, Inc. (ATEC) has announced its participation in upcoming investor conferences. The company will host one-on-one meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and will present at the 19th Annual Piper Sandler MedTech conference. This engagement reflects ATEC's commitment to investor relations.
Read more →ATECATEC to Report Second Quarter 2026 Financial Results on August 4, 2026
Alphatec Holdings, Inc. (ATEC) will report its second quarter 2026 financial results on August 4, 2026, after market close. The company is dedicated to innovative solutions in spine surgery. A live webcast will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
Read more →ATECATEC Refinances Existing Debt with Inaugural Bank Facility
ATEC has announced the refinancing of its existing debt through a new bank facility. This marks the company's inaugural engagement with a bank for such financing. The move aims to improve ATEC's financial flexibility and support its operational goals.
Read more →ATECATEC Reports First Quarter Financial Results
ATEC has released its financial results for the first quarter. The report includes various metrics and figures that reflect the company's performance during this period. However, specific details about revenue, expenses, or future projections were not disclosed in the article.
Read more →ATECATEC to Report First Quarter 2026 Financial Results on May 5, 2026
Alphatec Holdings, Inc. (ATEC) will report its first quarter 2026 financial results on May 5, 2026, after market close. A live webcast will be held at 1:30 p.m. PT, and analysts must register in advance for the Q&A session. Additionally, ATEC will participate in the Bank of America Securities 2026 Healthcare Conference on May 12.
Read more →ATEC▲ +5.9%on this news
ATEC Reports Fourth Quarter and Full-Year 2025 Financial Results
Alphatec Holdings, Inc. (ATEC) reported its financial results for the fourth quarter and full year 2025, highlighting a 25% increase in total revenue to $764 million. The company achieved a significant profit margin expansion and expects total revenue for 2026 to approximate $890 million. Despite a GAAP net loss of $143 million for 2025, ATEC reported positive free cash flow in the fourth quarter and projects continued growth with expected adjusted EBITDA of approximately $134 million for 2026. The report also details the launch of their Valence intraoperative platform and implications for future performance.
Read more →ATEC▼ -6.5%on this news
ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion
Alphatec Holdings, Inc. (ATEC) has entered a strategic partnership with Theradaptive, gaining exclusive U.S. rights to the OsteoAdapt platform for spinal fusion. This collaboration aims to enhance the efficacy of spinal surgeries through innovative regenerative medicine. Theradaptive is also initiating a Series B funding round to support clinical studies and commercialization efforts.
Read more →ATEC▼ -22.3%on this newsshared move
ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook
Alphatec Holdings, Inc. (ATEC) announced preliminary financial results for 2025, highlighting a total revenue increase of 25% to approximately $764 million. The company anticipates a further revenue growth to $890 million in 2026, driven by strong surgical revenue performance. Additionally, ATEC has secured exclusive U.S. distribution rights for Theradaptive's next-generation rhBMP-2 solution, OsteoAdapt. This acquisition aims to enhance the company's procedural offerings in spinal health, addressing challenges in the market concentration of biologics.
Read more →ATECATEC Mourns Passing of Board Member Jeffrey P. Rydin
Alphatec Holdings, Inc. announced the passing of Board member Jeffrey P. Rydin at the age of 59 due to a lengthy illness. Rydin was a crucial figure in ATEC's turnaround efforts, having joined the Board in 2017 and significantly influenced its strategic decisions. CEO Pat Miles expressed deep sorrow over the loss, highlighting Rydin's contributions and character, emphasizing his trustworthiness and commitment to both the company and his family. ATEC acknowledges the challenges of moving forward without his leadership during a critical period for the company.
Read more →ATECATEC Reports Third Quarter 2025 Financial Results And Raises Full-Year Guidance
Alphatec Holdings, Inc. (ATEC) reported its financial results for the third quarter of 2025, revealing a total revenue increase of 30%, reaching $197 million. Surgical revenue grew by 31%, signaling robust market demand and expanding surgeon adoption. The company raised its full-year guidance for total revenue to $760 million and adjusted EBITDA to approximately $91 million. The results demonstrate strong financial health with positive cash flow and an expanded gross margin.
Read more →ATECATEC Reports Second Quarter 2025 Financial Results And Raises Full-Year Guidance
Alphatec Holdings, Inc. (ATEC) announced its financial results for the second quarter of 2025, reporting a total revenue of $186 million, which represents a 27.5% increase from the previous year. Surgical revenue saw a significant rise of 29% to $168 million, driven by continued momentum in new surgeon adoption and innovative products. ATEC also raised its full-year revenue guidance to a projected $742 million, reflecting strong operational execution and a favorable market position.
Read more →ATECATEC Reports First Quarter 2025 Financial Results And Raises Full-Year Guidance
Alphatec Holdings, Inc. (ATEC) reported robust financial results for the first quarter of 2025, with total revenue reaching $169 million and surgical revenue rising by 24%. The company has raised its full-year guidance, now anticipating total revenue growth of 20% and non-GAAP adjusted EBITDA to improve to approximately $78 million. The successful refinancing of convertible debt to maturity in 2030 further solidifies ATEC's financial standing. Overall, the company demonstrates strong growth potential and positive management outlook for the remainder of the year.
Read more →ATECATEC Prices Upsized $350.0 Million Convertible Senior Notes Offering
Alphatec Holdings, Inc. (ATEC) announced the upsized pricing of its $350 million convertible senior notes offering due in 2030, increasing from the originally planned $300 million. The offering is set to settle on March 7, 2025, and features a low interest rate of 0.75% with the potential for noteholders to convert their notes into common stock. Notably, this offering aims to raise approximately $339 million for various corporate needs and includes capped call transactions to mitigate potential stock dilution. The initiative reflects strong investor interest, evidenced by the premium on the conversion price relative to existing stock prices.
Read more →ATECATEC Announces Proposed Convertible Senior Notes Offering
Alphatec Holdings, Inc. (ATEC) has announced a proposed offering of $300 million in convertible senior notes due 2030 to qualified institutional buyers. Additionally, an option to purchase up to $50 million in additional notes may be granted. The notes will be unsecured and accrue interest payable semi-annually. ATEC anticipates using a portion of the proceeds to fund capped call transactions, repurchase existing convertible notes, and for general corporate purposes. The offering is subject to market conditions and other regulatory requirements.
Read more →ATECATEC Reports Fourth Quarter and Full Year 2024 Financial Results
Alphatec Holdings, Inc. (ATEC) reported fourth quarter and full year 2024 financial results, highlighting a 27% increase in total revenue to $612 million. The company entered Japan's spine surgery market, achieving a successful surgery, and saw significant growth in surgical revenue and user adoption. ATEC estimates total revenue for 2025 to reach approximately $732 million, reflecting continued growth and positive free cash flow. The company remains focused on innovating and expanding within the spine care sector.
Read more →ATEC▲ +9.1%on this news
ATEC Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook
Alphatec Holdings, Inc. (ATEC) announced preliminary financial results for 2024, reflecting a 27% revenue growth to approximately $611 million. The company projects total revenue for 2025 of $732 million, marking an anticipated growth of 20%. Key drivers of growth include strong surgeon adoption and an increase in surgical volume. ATEC also indicates expected positive free cash flow for 2025, enhancing its financial outlook.
Read more →ATECATEC Reports Third Quarter 2024 Financial Results And Raises Full-Year Guidance Surgical revenue grew 30%; total revenue grew 27% Full-year revenue and profitability guidance increased Enhanced balance sheet flexibility
Alphatec Holdings, Inc. (ATEC) reported strong financial results for the third quarter of 2024, with surgical revenue up 30% and total revenue increasing by 27%. The company raised its full-year guidance, expecting total revenue to grow by 25% to $605 million. Additionally, ATEC improved its financial flexibility by expanding an existing term loan by $50 million. Despite these positive results, the company reported a net loss of $40 million and acknowledged uncertainties regarding future growth and product development.
Read more →ATECATEC Reports Second Quarter 2024 Financial Results And Raises Full-Year Guidance Surgical revenue grew 27% and drove total revenue growth of 25% to $146 million Full-year revenue and profitability guidance increased
Alphatec Holdings, Inc. (ATEC) reported significant second-quarter financial results for 2024, with total revenue reaching $146 million, a 25% increase driven by a 27% rise in surgical revenue. The company has raised its full-year guidance to an expected total revenue of $602 million, reflecting stronger anticipated performance. Notably, ATEC launched EOS Insight, aimed at improving spine surgeries, and saw a 20% growth in new surgeon adoption. Additionally, Keith Valentine has joined the Board of Directors, bringing over 30 years of industry experience.
Read more →About Alphatec Holdings, Inc.
Headquarters1950 CAMINO VIA ROBLE, CARLSBAD, CA
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next ATEC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime